|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2006-06-28 |
A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic Leukemia
This phase III trial compares the effect of the combination of blinatumomab with dasatinib and standard chemotherapy versus dasatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (PH+) or Philadelphia chromosome-like (Ph-Like) ABL-class B-Cell acute lymphoblastic leukemia (B-ALL). Blinatumomab is a bispecific antibody that binds to two different proteins-one on the surface of cancer cells and one on the surface of cells in the immune system. An antibody is a protein made by the immune system to help fight infections and other harmful processes/cells/molecules. Blinatumomab may bind to the cancer cell and a T cell (which plays a key role in the immune system's fighting response) at the same time. Blinatumomab may strengthen the immune system's ability to fight cancer cells by activating the body's own immune cells to destroy the tumor. Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Giving blinatumomab and dasatinib in combination with standard chemotherapy may work better in treating patients with PH+ or Ph-Like ABL-class B-ALL compared to dasatinib and chemotherapy alone.
100 项与 FYN x Tyrosine kinase x c-Kit x YES1 x LCK x Bcr-Abl x SRC x PDGFRβ x EphA2 x Protein kinases 相关的临床结果
100 项与 FYN x Tyrosine kinase x c-Kit x YES1 x LCK x Bcr-Abl x SRC x PDGFRβ x EphA2 x Protein kinases 相关的转化医学
0 项与 FYN x Tyrosine kinase x c-Kit x YES1 x LCK x Bcr-Abl x SRC x PDGFRβ x EphA2 x Protein kinases 相关的专利(医药)